Similarity of uterine mucosa changes in patients treated by Raloxifen and Tamoxifen

Anticancer Research

Volumn 22, Issue 2 B, 2002, Pages 1121-1125

  Willèn, Roger ^a   Willlèn, Helena ^a   Lindahl, Bengt ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Histopathology; Polyps; Raloxifen; Uterine mucosa

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CASE REPORT; CELL PROLIFERATION; ENDOMETRIUM; FEMALE; HISTOPATHOLOGY; HORMONAL REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENOPAUSAL SYNDROME; MITOSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

AGED; FEMALE; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; POLYPS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; UTERINE NEOPLASMS; UTERUS;

EID: 0036327135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Late effects of adjuvant therapy for breast cancer
2. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
3. Selective estrogen receptor modulators (SERMS) in clinical practice
4. The multifaceted mechanisms of estradiol and estrogen receptor signalling
5. Effects of raloxifen on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
6. Effects of raloxifen hydrochloride on the endometrium of postmenopausal women
7. How to manage the menopause following therapy for breast cancer. Is raloxifen a safe alternative?
8. Raloxifene. A review of its use in postmenopausal osteoporosis
9. Histopathological findings in thickened endometria, as measured by ultrasound in asymptomatic, postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen
10. Long-term effects of raloxifen on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Three-yar data from 2 double-blind, randomized, placebo-controlled trials
11. Continued breast cancer risk reduction in postmenopausal women treated with raloxifen: 4-Year results from the MORE trial
12. Differential response of estrogen receptor alfa and estrogen receptor beta to partial agonists-antagonists